Kendice Ip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kendice Ip has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Daniel Banov
Professional Compounding Centers of America (PCCA), Houston, United States
7 shared publications- Maria Carvalho
Professional Compounding Centers of America (PCCA), Houston, TX 77099, USA
6 shared publications - Daniel Banov
Professional Compounding Centers of America (PCCA), Houston, TX 77099, USA
4 shared publications - Guiyun Song
Professional Compounding Centers of America (PCCA), Houston, TX 77099, USA
4 shared publications Ashley Shan
Professional Compounding Centers of America, Houston, Texas
3 shared publications- Ashley Shan
Professional Compounding Centers of America (PCCA), Houston, TX 77099, USA
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1) , 57
In vitro performance evaluation of a self-emulsifying anhydrous suspension vehicle for enteral drug administration
- 1 September 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1) , 57
Open AccessIn vitro performance evaluation of a self-emulsifying anhydrous suspension vehicle for enteral drug administration
- Open Access
- 7 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 585
Comprehensive Evaluation of a Mucoadhesive Self-Emulsifying Anhydrous Base for Vaginal Drug Delivery
Background/Objectives: Compounded vaginal creams are widely used for conditions such as hormone replacement therapy, vaginal dryness, low libido, vaginal infections, etc. Recent research highlights the potential of using anhydrous bases to extend shelf life, particularly when combined with self-emulsifying and mucoadhesive properties that improve mucosal retention and enhance drug bioavailability. This study provides in vitro and ex vivo evaluation of an anhydrous vaginal base. Methods: Key quality indicators such as irritation potential, leakage potential, pH compatibility, mucoadhesion, and self-emulsification were assessed using the chorioallantoic membrane Hen’s Egg Test, MTT assay, texture analysis, and fluorescence microscopy. Results: The anhydrous vaginal base demonstrated high cell viability (>78%) and non-irritant potential (IS = 2.5) in in vitro assays. It maintained physiological vaginal pH (4.56 ± 0.05), showed strong mucoadhesive properties comparable to commercial products, and exhibited minimal leakage. Ex vivo studies confirmed its prolonged retention on vaginal tissues. The anhydrous vaginal base formed stable emulsions upon contact with vaginal fluid simulant, effectively distributing both lipophilic and hydrophilic compounds. Conclusions: Compared to water-containing bases, an anhydrous vaginal base shows advantages: longer retention time and lower leakage; adaptability to varying vaginal fluid levels; and efficient dispersion of both hydrophilic and lipophilic active pharmaceutical ingredients. These features support its potential use in compounded vaginal products, minimizing stability risks and enhancing patient compliance and therapeutic outcomes.
- 7 April 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 585
Open AccessComprehensive Evaluation of a Mucoadhesive Self-Emulsifying Anhydrous Base for Vaginal Drug Delivery
Background/Objectives: Compounded vaginal creams are widely used for conditions such as hormone replacement therapy, vaginal dryness, low libido, vaginal infections, etc. Recent research highlights the potential of using anhydrous bases to extend shelf life, particularly when combined with self-emulsifying and mucoadhesive properties that improve mucosal retention and enhance drug bioavailability. This study provides in vitro and ex vivo evaluation of an anhydrous vaginal base. Methods: Key quality indicators such as irritation potential, leakage potential, pH compatibility, mucoadhesion, and self-emulsification were assessed using the chorioallantoic membrane Hen’s Egg Test, MTT assay, texture analysis, and fluorescence microscopy. Results: The anhydrous vaginal base demonstrated high cell viability (>78%) and non-irritant potential (IS = 2.5) in in vitro assays. It maintained physiological vaginal pH (4.56 ± 0.05), showed strong mucoadhesive properties comparable to commercial products, and exhibited minimal leakage. Ex vivo studies confirmed its prolonged retention on vaginal tissues. The anhydrous vaginal base formed stable emulsions upon contact with vaginal fluid simulant, effectively distributing both lipophilic and hydrophilic compounds. Conclusions: Compared to water-containing bases, an anhydrous vaginal base shows advantages: longer retention time and lower leakage; adaptability to varying vaginal fluid levels; and efficient dispersion of both hydrophilic and lipophilic active pharmaceutical ingredients. These features support its potential use in compounded vaginal products, minimizing stability risks and enhancing patient compliance and therapeutic outcomes.
- Open Access
- 6 April 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Mastering particle size analysis: lessons, challenges, and future directions from the FDA–CRCG workshop
Particle-size distribution (PSD) measurement is a cornerstone of pharmaceutical development and regulatory assessment, influencing formulation stability, dissolution, product quality, and performance. Yet the seemingly straightforward nature of “size measurements” often conceals substantial scientific and practical complexity. To strengthen shared understanding and advance good measurement practices, the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a two-day hybrid workshop, “Mastering Particle Size Analysis: A Step-by-Step Illustration of Techniques and Best Practices,” held on September 23–24, 2025. The workshop brought together scientists from regulatory agencies, industry, academia, and instrument manufacturers to examine the principles, data interpretation, and analytical procedure robustness of two widely used techniques—Dynamic Light Scattering (DLS) and Laser Diffraction (LD). The program integrated scientific lectures, vendor-led demonstrations, and structured small-group discussions organized around real-world case studies. Prior to the workshop, participating vendors conducted independent characterization of five pre-workshop materials representing diverse formulation types, providing a shared baseline for comparison. In total, 2823 participants registered for the workshop, including 127 for in-person attendance and 2696 for virtual attendance from across the global pharmaceutical community. Of those that registered, 119 participants attended in-person, and 1464 attended virtually during the two days. Discussions throughout the workshop emphasized that PSD data cannot be interpreted in isolation because what is measured depends on the model assumption, sample condition, and analytical purpose. Participants concluded that reliable characterization demands “fit-for-purpose” analytical procedure design, transparent reporting, and a clear linkage between measurements and material function. Major outcomes included (i) recognition that methodological transparency outweighs pursuit of a single “true” particle size; (ii) identification of the dominant sources of inter-laboratory variability; and (iii) broad consensus on the need for harmonized terminology, validation criteria, and reporting expectations. The workshop closed with collective commitments to prepare a community white paper and to initiate an inter-laboratory study aimed at improving comparability of PSD data across techniques, platforms, and laboratories—steps that will help ensure measurement integrity and regulatory confidence in complex drug development.
- 6 April 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Open AccessMastering particle size analysis: lessons, challenges, and future directions from the FDA–CRCG workshop
Particle-size distribution (PSD) measurement is a cornerstone of pharmaceutical development and regulatory assessment, influencing formulation stability, dissolution, product quality, and performance. Yet the seemingly straightforward nature of “size measurements” often conceals substantial scientific and practical complexity. To strengthen shared understanding and advance good measurement practices, the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a two-day hybrid workshop, “Mastering Particle Size Analysis: A Step-by-Step Illustration of Techniques and Best Practices,” held on September 23–24, 2025. The workshop brought together scientists from regulatory agencies, industry, academia, and instrument manufacturers to examine the principles, data interpretation, and analytical procedure robustness of two widely used techniques—Dynamic Light Scattering (DLS) and Laser Diffraction (LD). The program integrated scientific lectures, vendor-led demonstrations, and structured small-group discussions organized around real-world case studies. Prior to the workshop, participating vendors conducted independent characterization of five pre-workshop materials representing diverse formulation types, providing a shared baseline for comparison. In total, 2823 participants registered for the workshop, including 127 for in-person attendance and 2696 for virtual attendance from across the global pharmaceutical community. Of those that registered, 119 participants attended in-person, and 1464 attended virtually during the two days. Discussions throughout the workshop emphasized that PSD data cannot be interpreted in isolation because what is measured depends on the model assumption, sample condition, and analytical purpose. Participants concluded that reliable characterization demands “fit-for-purpose” analytical procedure design, transparent reporting, and a clear linkage between measurements and material function. Major outcomes included (i) recognition that methodological transparency outweighs pursuit of a single “true” particle size; (ii) identification of the dominant sources of inter-laboratory variability; and (iii) broad consensus on the need for harmonized terminology, validation criteria, and reporting expectations. The workshop closed with collective commitments to prepare a community white paper and to initiate an inter-laboratory study aimed at improving comparability of PSD data across techniques, platforms, and laboratories—steps that will help ensure measurement integrity and regulatory confidence in complex drug development.
- Open Access
- 19 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 596
In Vitro Percutaneous Absorption of Permeation-Enhancing Estrogen Formulations
Background/Objectives: Hormone Replacement Therapy (HRT) is commonly prescribed to women in need to restore the deficiency of hormones. Estrogens, in particular estradiol (E2) and estriol (E3), are associated with side effects when given orally. As such, estrogen is topically applied on the skin for the delivery of the hormone. The objective of this in vitro study is to evaluate the percutaneous absorption of compounded estradiol 0.06% and bi-est E3/E2 0.1%/0.06% in aqueous and anhydrous proprietary permeation-enhancing bases, in comparison with the commercially available estradiol transdermal gel (ESTROGel®). Methods: The In Vitro Permeation Test (IVPT) was used and validated for the objectives of this study. The strength of estradiol/estriol in five test formulations was determined using Ultra Performance Liquid Chromatography (UPLC). Results: ESTROGel exhibited a rapid increase in the rate of skin absorption of estradiol within 0.5 h post-application. This peak was followed by a rapid decline in flux within 4 h, and then a slower decline by 16 h post-application. The initial rapid increase for ESTROGel was much faster than the rate of the four test compounded formulations, which each exhibited a slow and steady increase in the rate of skin absorption of estradiol with a peak flux within 6 h, and a steady absorption within 16 h of application. Conclusions: The compounded bases facilitated a steady percutaneous absorption of estradiol, without quick peaking or declining, which is one of the desired characteristics in HRT. Compounding pharmacists and practitioners may consider estradiol compounded formulations as a viable option for hormone delivery to patients.
- 19 April 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (4) , 596
Open AccessIn Vitro Percutaneous Absorption of Permeation-Enhancing Estrogen Formulations
Background/Objectives: Hormone Replacement Therapy (HRT) is commonly prescribed to women in need to restore the deficiency of hormones. Estrogens, in particular estradiol (E2) and estriol (E3), are associated with side effects when given orally. As such, estrogen is topically applied on the skin for the delivery of the hormone. The objective of this in vitro study is to evaluate the percutaneous absorption of compounded estradiol 0.06% and bi-est E3/E2 0.1%/0.06% in aqueous and anhydrous proprietary permeation-enhancing bases, in comparison with the commercially available estradiol transdermal gel (ESTROGel®). Methods: The In Vitro Permeation Test (IVPT) was used and validated for the objectives of this study. The strength of estradiol/estriol in five test formulations was determined using Ultra Performance Liquid Chromatography (UPLC). Results: ESTROGel exhibited a rapid increase in the rate of skin absorption of estradiol within 0.5 h post-application. This peak was followed by a rapid decline in flux within 4 h, and then a slower decline by 16 h post-application. The initial rapid increase for ESTROGel was much faster than the rate of the four test compounded formulations, which each exhibited a slow and steady increase in the rate of skin absorption of estradiol with a peak flux within 6 h, and a steady absorption within 16 h of application. Conclusions: The compounded bases facilitated a steady percutaneous absorption of estradiol, without quick peaking or declining, which is one of the desired characteristics in HRT. Compounding pharmacists and practitioners may consider estradiol compounded formulations as a viable option for hormone delivery to patients.
- 1 January 2025
- Vol. 29 (4) , 279-290
Stability Study of Pediatric Oral Suspensions Formulated with PCCA SuspendIt Vehicle Used for the Treatment of Cardiovascular Disease.
The pharmaceutical landscape in pediatric cardiology involves the use of several key active pharmaceutical ingredients (APIs) that have been carefully selected to address the diverse range of conditions encountered. Hydrochlorothiazide, captopril and metoprolol are part of this list, selected based on stringent criteria that included proven efficacy, a favorable safety profile, and suitability for pediatric use. These active ingredients belong to different pharmacological groups - an angiotensin-converting enzyme inhibitor (captopril), a thiazide diuretic (hydrochlorothiazide) and a beta-blocker (metoprolol) - and are used to treat a variety of cardiovascular problems. Commercial pharmaceutical forms of these drugs are not available for pediatric patients, leaving a gap in dosing options. Therefore, the primary means of serving this population is through extemporaneous compounding of suspensions using pure drug powder or commercial tablets. The objective of this study was to investigate the physicochemical and microbiological stability of three distinct compounded pediatric oral cardiovascular suspensions, that contain captopril, hydrochlorothiazide, and metoprolol tartrate, and are formulated using PCCA SuspendIt. The study design included two concentrations of each API to provide stability investigation over a bracketed concentration range: captopril (1 mg/mL and 5 mg/mL), hydrochlorothiazide (5 mg/mL and 10 mg/mL), and metoprolol (1 mg/mL and 10 mg/mL). Ultra-high-performance liquid chromatography (UHPLC) methods were developed and validated for the determination of the chemical stability of captopril, hydrochlorothiazide, and metoprolol in SuspendIt. Samples of hydrochlorothiazide and metoprolol suspensions were stored in plastic amber prescription bottles at the temperature 25±2 °C, relative humidity 60±5 %, and captopril suspensions at 5±3 °C. Samples were analyzed at the following time points: 0, 7, 14, 30, 60, 90, and 180 days. Various forced degradation conditions were employed, including acidic, basic, oxidative, and heat degradation. The results revealed that potential interfering degradants do not affect the analytical peaks of the drug substance, and the factors contributing to the significant degradation of the drug substance in the suspension were identified. Physical properties such as pH and appearance were also observed. All measurements were performed in duplicate. Antimicrobial efficacy tests were performed to control microbial growth during storage. The current study demonstrates that SuspendIt cardiovascular suspensions are physically, chemically and microbiologically stable for 180 days for captopril (when stored in the refrigerator) and hydrochlorothiazide and metoprolol tartrate (when stored at room temperature), retaining not less than 90% of the labeled drug concentrations. This study provides a viable compounded alternative for hydrochlorothiazide, metoprolol tartrate and captopril in a liquid dosage form with an adequate beyond-use-date to meet patient needs.
- 1 January 2025
- Vol. 29 (4) , 279-290
Stability Study of Pediatric Oral Suspensions Formulated with PCCA SuspendIt Vehicle Used for the Treatment of Cardiovascular Disease.
The pharmaceutical landscape in pediatric cardiology involves the use of several key active pharmaceutical ingredients (APIs) that have been carefully selected to address the diverse range of conditions encountered. Hydrochlorothiazide, captopril and metoprolol are part of this list, selected based on stringent criteria that included proven efficacy, a favorable safety profile, and suitability for pediatric use. These active ingredients belong to different pharmacological groups - an angiotensin-converting enzyme inhibitor (captopril), a thiazide diuretic (hydrochlorothiazide) and a beta-blocker (metoprolol) - and are used to treat a variety of cardiovascular problems. Commercial pharmaceutical forms of these drugs are not available for pediatric patients, leaving a gap in dosing options. Therefore, the primary means of serving this population is through extemporaneous compounding of suspensions using pure drug powder or commercial tablets. The objective of this study was to investigate the physicochemical and microbiological stability of three distinct compounded pediatric oral cardiovascular suspensions, that contain captopril, hydrochlorothiazide, and metoprolol tartrate, and are formulated using PCCA SuspendIt. The study design included two concentrations of each API to provide stability investigation over a bracketed concentration range: captopril (1 mg/mL and 5 mg/mL), hydrochlorothiazide (5 mg/mL and 10 mg/mL), and metoprolol (1 mg/mL and 10 mg/mL). Ultra-high-performance liquid chromatography (UHPLC) methods were developed and validated for the determination of the chemical stability of captopril, hydrochlorothiazide, and metoprolol in SuspendIt. Samples of hydrochlorothiazide and metoprolol suspensions were stored in plastic amber prescription bottles at the temperature 25±2 °C, relative humidity 60±5 %, and captopril suspensions at 5±3 °C. Samples were analyzed at the following time points: 0, 7, 14, 30, 60, 90, and 180 days. Various forced degradation conditions were employed, including acidic, basic, oxidative, and heat degradation. The results revealed that potential interfering degradants do not affect the analytical peaks of the drug substance, and the factors contributing to the significant degradation of the drug substance in the suspension were identified. Physical properties such as pH and appearance were also observed. All measurements were performed in duplicate. Antimicrobial efficacy tests were performed to control microbial growth during storage. The current study demonstrates that SuspendIt cardiovascular suspensions are physically, chemically and microbiologically stable for 180 days for captopril (when stored in the refrigerator) and hydrochlorothiazide and metoprolol tartrate (when stored at room temperature), retaining not less than 90% of the labeled drug concentrations. This study provides a viable compounded alternative for hydrochlorothiazide, metoprolol tartrate and captopril in a liquid dosage form with an adequate beyond-use-date to meet patient needs.
- Open Access
- 6 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 621
Testosterone Therapy for Late-Onset Hypogonadism: A Clinical, Biological, and Analytical Approach Using Compounded Testosterone 0.5–20% Topical Gels
Testosterone is integral to men’s sexual and overall health, but there is a gradual decline in the ageing male. The topical administration of testosterone is a valuable option as a supplement (replacement) therapy to alleviate hypogonadal symptoms. The clinical efficacy of a compounded testosterone 5% topical gel was assessed retrospectively in a male patient in his seventies by evaluating the laboratory testing of the serum total testosterone and the results of a validated androgen deficiency questionnaire. After treatment, the patient’s hypogonadal symptoms improved and the serum total testosterone level achieved was considered clinically optimal. The skin permeation of the testosterone topical gel (biological testing) was evaluated in vitro using the Franz finite dose model and human cadaver skin, and it is shown that testosterone can penetrate into and through ex vivo human skin. Testosterone therapy is often prescribed for extended periods, and consequently, it is crucial to determine the beyond-use date of the compounded formulations. The analytical testing involved a valid, stability-indicating assay method for compounded testosterone 0.5% and 20% topical gels. This multidisciplinary study shows evidence supporting topically applied testosterone’s clinical efficacy and the compounded formulations’ extended stability. Personalized, topical testosterone therapy is a promising alternative in current therapeutics for hypogonadal patients.
- 6 May 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (5) , 621
Open AccessTestosterone Therapy for Late-Onset Hypogonadism: A Clinical, Biological, and Analytical Approach Using Compounded Testosterone 0.5–20% Topical Gels
Testosterone is integral to men’s sexual and overall health, but there is a gradual decline in the ageing male. The topical administration of testosterone is a valuable option as a supplement (replacement) therapy to alleviate hypogonadal symptoms. The clinical efficacy of a compounded testosterone 5% topical gel was assessed retrospectively in a male patient in his seventies by evaluating the laboratory testing of the serum total testosterone and the results of a validated androgen deficiency questionnaire. After treatment, the patient’s hypogonadal symptoms improved and the serum total testosterone level achieved was considered clinically optimal. The skin permeation of the testosterone topical gel (biological testing) was evaluated in vitro using the Franz finite dose model and human cadaver skin, and it is shown that testosterone can penetrate into and through ex vivo human skin. Testosterone therapy is often prescribed for extended periods, and consequently, it is crucial to determine the beyond-use date of the compounded formulations. The analytical testing involved a valid, stability-indicating assay method for compounded testosterone 0.5% and 20% topical gels. This multidisciplinary study shows evidence supporting topically applied testosterone’s clinical efficacy and the compounded formulations’ extended stability. Personalized, topical testosterone therapy is a promising alternative in current therapeutics for hypogonadal patients.
- Open Access
- 23 February 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (3) , e13589
Evaluation of the in vitro human skin percutaneous absorption of ketoprofen in topical anhydrous and aqueous gels
Background: Ketoprofen is a nonsteroidal anti‐inflammatory drug used for the treatment of acute and chronic pain associated with inflammatory conditions. This study aims to evaluate the in vitro percutaneous absorption of ketoprofen 10% formulated in proprietary anhydrous and aqueous gels using the Franz skin finite dose model. Materials and Methods: The anhydrous gel was initially characterized for cytotoxicity using EpiDerm skin tissue model by cell proliferation assay and Western blot analysis. The Ultra Performance Liquid Chromatography method for measuring ketoprofen was validated and the stability of ketoprofen 10% in the anhydrous gel formulation was evaluated at 5°C and 25°C for 181 days. The percutaneous absorption of ketoprofen was determined using donated human skin. The tissue sections were mounted within Franz diffusion cells. A variable finite dose of each ketoprofen formulation in either anhydrous or aqueous gel was applied to the skin sections and receptor solutions were collected at various time points. Results: Cell proliferation assay showed minimal cell death when EpiDerm skin tissue was exposed to the anhydrous gel for 24 h; the levels of protein markers of cell proliferation were not affected after 17‐h exposure. Ketoprofen was stable in the anhydrous gel when stored at 5°C and 25°C. When compounded in the anhydrous and aqueous gels, ketoprofen had mean flux rate of 2.22 and 2.50 μg/cm 2 /h, respectively, after 48 h. The drug was distributed to the epidermis and dermis sections of the skin. Both the anhydrous and aqueous gels facilitated the percutaneous absorption of ketoprofen without statistically significant differences. Conclusion: The anhydrous gel can be used as a base to facilitate the transdermal delivery of ketoprofen. Although the anhydrous and aqueous gels can deliver a similar amount of ketoprofen, the anhydrous gel (water activity below 0.6) allows for extended default beyond‐use‐date of compounding preparations.
- 23 February 2024
- Published by Wiley in Skin Research and Technology
- Vol. 30 (3) , e13589
Open AccessEvaluation of the in vitro human skin percutaneous absorption of ketoprofen in topical anhydrous and aqueous gels
Background: Ketoprofen is a nonsteroidal anti‐inflammatory drug used for the treatment of acute and chronic pain associated with inflammatory conditions. This study aims to evaluate the in vitro percutaneous absorption of ketoprofen 10% formulated in proprietary anhydrous and aqueous gels using the Franz skin finite dose model. Materials and Methods: The anhydrous gel was initially characterized for cytotoxicity using EpiDerm skin tissue model by cell proliferation assay and Western blot analysis. The Ultra Performance Liquid Chromatography method for measuring ketoprofen was validated and the stability of ketoprofen 10% in the anhydrous gel formulation was evaluated at 5°C and 25°C for 181 days. The percutaneous absorption of ketoprofen was determined using donated human skin. The tissue sections were mounted within Franz diffusion cells. A variable finite dose of each ketoprofen formulation in either anhydrous or aqueous gel was applied to the skin sections and receptor solutions were collected at various time points. Results: Cell proliferation assay showed minimal cell death when EpiDerm skin tissue was exposed to the anhydrous gel for 24 h; the levels of protein markers of cell proliferation were not affected after 17‐h exposure. Ketoprofen was stable in the anhydrous gel when stored at 5°C and 25°C. When compounded in the anhydrous and aqueous gels, ketoprofen had mean flux rate of 2.22 and 2.50 μg/cm 2 /h, respectively, after 48 h. The drug was distributed to the epidermis and dermis sections of the skin. Both the anhydrous and aqueous gels facilitated the percutaneous absorption of ketoprofen without statistically significant differences. Conclusion: The anhydrous gel can be used as a base to facilitate the transdermal delivery of ketoprofen. Although the anhydrous and aqueous gels can deliver a similar amount of ketoprofen, the anhydrous gel (water activity below 0.6) allows for extended default beyond‐use‐date of compounding preparations.
- Open Access
- 20 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2642
Analysis of the Physical Characteristics of an Anhydrous Vehicle for Compounded Pediatric Oral Liquids
The paucity of suitable drug formulations for pediatric patients generates a need for customized, compounded medications. This research study was set out to comprehensively analyze the physical properties of the new, proprietary anhydrous oral vehicle SuspendIt® Anhydrous, which was designed for compounding pediatric oral liquids. A wide range of tests was used, including sedimentation volume, viscosity, droplet size after dispersion in simulated gastric fluid, microscopic examination and content uniformity measurements to evaluate the properties of the anhydrous vehicle. The results showed that the vehicle exhibited consistent physical properties under varying conditions and maintained stability over time. This can be attributed to the unique blend of excipients in its formulation, which not only maintain its viscosity but also confer thixotropic behavior. The unique combination of viscous, thixotropic and self-emulsifying properties allows for rapid redispersibility, sedimentation stability, accurate dosing, potential drug solubility, dispersion and promotion of enhanced gastrointestinal distribution and absorption. Furthermore, the vehicle demonstrated long-term sedimentation stability and content uniformity for a list of 13 anhydrous suspensions. These results suggest that the anhydrous oral vehicle could serve as a versatile base for pediatric formulation, potentially filling an important gap in pediatric drug delivery. Future studies can further investigate its compatibility, stability and performance with other drugs and in different clinical scenarios.
- 20 November 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (11) , 2642
Open AccessAnalysis of the Physical Characteristics of an Anhydrous Vehicle for Compounded Pediatric Oral Liquids
The paucity of suitable drug formulations for pediatric patients generates a need for customized, compounded medications. This research study was set out to comprehensively analyze the physical properties of the new, proprietary anhydrous oral vehicle SuspendIt® Anhydrous, which was designed for compounding pediatric oral liquids. A wide range of tests was used, including sedimentation volume, viscosity, droplet size after dispersion in simulated gastric fluid, microscopic examination and content uniformity measurements to evaluate the properties of the anhydrous vehicle. The results showed that the vehicle exhibited consistent physical properties under varying conditions and maintained stability over time. This can be attributed to the unique blend of excipients in its formulation, which not only maintain its viscosity but also confer thixotropic behavior. The unique combination of viscous, thixotropic and self-emulsifying properties allows for rapid redispersibility, sedimentation stability, accurate dosing, potential drug solubility, dispersion and promotion of enhanced gastrointestinal distribution and absorption. Furthermore, the vehicle demonstrated long-term sedimentation stability and content uniformity for a list of 13 anhydrous suspensions. These results suggest that the anhydrous oral vehicle could serve as a versatile base for pediatric formulation, potentially filling an important gap in pediatric drug delivery. Future studies can further investigate its compatibility, stability and performance with other drugs and in different clinical scenarios.
- 30 October 2019
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (2) , 145-154
In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis
Psoriasis is a multifactorial skin disease involving abnormal cell proliferation and inflammation; an efficacious topical treatment is yet to be identified. A formulation containing 1% Naltrexone HCl in XemaTop™ base was compounded, characterized and evaluated in vitro as a possible treatment for psoriasis. A three-dimensional psoriasis tissue model was exposed to the formulation for 2 or 5 days and analyzed for the level of markers of cellular proliferation, and inflammatory cytokine IL-6. Using immunohistochemical staining, the level of Ki67 protein significantly decreased in the drug-treated tissues. Western blot analysis showed 86% and 53% down-regulation of other proliferation markers PCNA and CYCLIN D1, respectively, after 5-day exposure. The pro-survival Wnt/β-catenin pathway was compromised as indicated by 57% decrease in the level of β-CATENIN and down-regulation of its down-stream targets including CYCLIN D1 (decreased by 53%), c-MYC (63%), c-JUN (92%) and MET (96%) proteins. Likewise, the PI3K/AKT/mTOR pathway was significantly inhibited by 1% Naltrexone HCl in XemaTop™, suggesting protein synthesis was affected. The production of IL-6 was inhibited by 70% in drug-treated tissues. These results suggest that the compounded drug is efficacious in down-regulating molecular markers associated with the pathogenesis of psoriasis. Low-dose Naltrexone in XemaTop™ was stable within 180 days when stored under refrigerated or ambient conditions. These results provide a basis for a clinical evaluation of 1% Naltrexone HCl in XemaTop™ in psoriasis patients.
- 30 October 2019
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (2) , 145-154
In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis
Psoriasis is a multifactorial skin disease involving abnormal cell proliferation and inflammation; an efficacious topical treatment is yet to be identified. A formulation containing 1% Naltrexone HCl in XemaTop™ base was compounded, characterized and evaluated in vitro as a possible treatment for psoriasis. A three-dimensional psoriasis tissue model was exposed to the formulation for 2 or 5 days and analyzed for the level of markers of cellular proliferation, and inflammatory cytokine IL-6. Using immunohistochemical staining, the level of Ki67 protein significantly decreased in the drug-treated tissues. Western blot analysis showed 86% and 53% down-regulation of other proliferation markers PCNA and CYCLIN D1, respectively, after 5-day exposure. The pro-survival Wnt/β-catenin pathway was compromised as indicated by 57% decrease in the level of β-CATENIN and down-regulation of its down-stream targets including CYCLIN D1 (decreased by 53%), c-MYC (63%), c-JUN (92%) and MET (96%) proteins. Likewise, the PI3K/AKT/mTOR pathway was significantly inhibited by 1% Naltrexone HCl in XemaTop™, suggesting protein synthesis was affected. The production of IL-6 was inhibited by 70% in drug-treated tissues. These results suggest that the compounded drug is efficacious in down-regulating molecular markers associated with the pathogenesis of psoriasis. Low-dose Naltrexone in XemaTop™ was stable within 180 days when stored under refrigerated or ambient conditions. These results provide a basis for a clinical evaluation of 1% Naltrexone HCl in XemaTop™ in psoriasis patients.
- 16 May 2019
- Vol. 23 (2) , 167-175
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure.
Methylcobalamin, one of the two active forms of vitamin B12, is the most effective analog in permeation and in transportation of neurons in subcellular organelles. Formulations of methylcobalamin are only commercially available in a few countries, which make them inaccessible for most patients. Extemporaneously prepared injections become the only option for those patients. The objective of this work is to study the physical and chemical (ultrahigh- performance liquid chromatography stability-indicating method) stabilities of methylcobalamin injections in the presence and absence of preservative during 181 days (considering the stability limit as 90% of initial concentration of methylcobalamin). The light exposure stability of injections in amber serum vials or clear syringes, solution in amber or clear glassware under typical pharmacy, clinical, and laboratory settings are also presented. Methylcobalamin injections, regardless of the concentrations and inactive ingredients, remained stable for at least 181 days at room temperature when stored in amber serum vials and protected from light. These experimental data suggested that the methylcobalamin injection solutions should be protected from light completely and light exposure in pharmacy, clinical, and laboratory setting should be minimized.
- 16 May 2019
- Vol. 23 (2) , 167-175
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure.
Methylcobalamin, one of the two active forms of vitamin B12, is the most effective analog in permeation and in transportation of neurons in subcellular organelles. Formulations of methylcobalamin are only commercially available in a few countries, which make them inaccessible for most patients. Extemporaneously prepared injections become the only option for those patients. The objective of this work is to study the physical and chemical (ultrahigh- performance liquid chromatography stability-indicating method) stabilities of methylcobalamin injections in the presence and absence of preservative during 181 days (considering the stability limit as 90% of initial concentration of methylcobalamin). The light exposure stability of injections in amber serum vials or clear syringes, solution in amber or clear glassware under typical pharmacy, clinical, and laboratory settings are also presented. Methylcobalamin injections, regardless of the concentrations and inactive ingredients, remained stable for at least 181 days at room temperature when stored in amber serum vials and protected from light. These experimental data suggested that the methylcobalamin injection solutions should be protected from light completely and light exposure in pharmacy, clinical, and laboratory setting should be minimized.